SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Chenshu Lu, Ke Tang, Yan Li, Peng Li, Ziyun Lin, Dali Yin, Xiaoguang Chen, Haihong Huang, Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents, European Journal of Medicinal Chemistry, 2014, 77, 351

    CrossRef

  2. 2
    Ahmed Hamed Salem, Denise Koenig, Dawn Carlson, Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients, Clinical Pharmacokinetics, 2014, 53, 4, 347

    CrossRef

  3. 3
    Yi-Lin Chiu, Patricia LoRusso, Balakrishna Hosmane, Justin L. Ricker, Walid Awni, Dawn M. Carlson, Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors, Cancer Chemotherapy and Pharmacology, 2014, 73, 1, 213

    CrossRef

  4. 4
    Muzaffar Iqbal, Essam Ezzeldin, Tanveer A Wani, Nasr Y Khalil, Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS, Chemistry Central Journal, 2014, 8, 1, 13

    CrossRef

  5. 5
    Jean K. Lee, Ghassan K. Abou-Alfa, An Update on Clinical Trials in the Treatment of Advanced Hepatocellular Carcinoma, Journal of Clinical Gastroenterology, 2013, 47, S16

    CrossRef

  6. 6
    Sang Jun Suh, Hyung Joon Yim, Current Status of Molecular Targeted Therapies in Hepatocellular Carcinoma, The Korean Journal of Gastroenterology, 2013, 61, 3, 136

    CrossRef

  7. 7
    Yasunari Hiramine, Tsutomu Tamai, Yasushi Imamura, Yoshirou Baba, Takuya Hiwaki, Hiroka Yamashita, Yukihiko Sho, Kenji Tahara, Ichiro Kanetsuki, Hirohito Tsubouchi, Efficacy and optimal treatment sequence of Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, Kanzo, 2013, 54, 4, 233

    CrossRef

  8. 8
    Yi-Lin Chiu, Dawn M. Carlson, Rajendra S. Pradhan, Justin L. Ricker, Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma, Clinical Therapeutics, 2013, 35, 11, 1770

    CrossRef

  9. 9
    Gaetano Bertino, Isidoro Di Carlo, Annalisa Ardiri, Giuseppe Stefano Calvagno, Shirin Demma, Giulia Malaguarnera, Nicoletta Bertino, Mariano Malaguarnera, Adriana Toro, Michele Malaguarnera, Systemic therapies in hepatocellular carcinoma: present and future, Future Oncology, 2013, 9, 10, 1533

    CrossRef

  10. 10
    Omar Abdel-Rahman, Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside, Journal of the Egyptian National Cancer Institute, 2013, 25, 4, 165

    CrossRef

  11. 11
    Ghassan K Abou-Alfa, Alan P Venook, The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?, The Lancet Oncology, 2013, 14, 7, e283

    CrossRef

  12. 12
    Dawn Qingqing Chong, Iain Beehuat Tan, Su-Pin Choo, Han Chong Toh, The evolving landscape of therapeutic drug development for hepatocellular carcinoma, Contemporary Clinical Trials, 2013, 36, 2, 605

    CrossRef

  13. 13
    Francesco Torino, Agnese Barnabei, Rosamaria Paragliola, Roberto Baldelli, Marialuisa Appetecchia, Salvatore Maria Corsello, Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs, Thyroid, 2013, 23, 11, 1345

    CrossRef

  14. 14
    Noriko Makita, Taroh Iiri, Tyrosine Kinase Inhibitor–Induced Thyroid Disorders: A Review and Hypothesis, Thyroid, 2013, 23, 2, 151

    CrossRef